Last reviewed · How we verify
Biosensors Europe SA — Portfolio Competitive Intelligence Brief
0 marketed
0 filed
1 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| Dual Anti Platelet Therapy | Dual Anti Platelet Therapy | phase 3 | Antiplatelet agent combination | Thromboxane A2 pathway and P2Y12 receptor | Cardiovascular |
Therapeutic area mix
- Cardiovascular · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Beijing Tiantan Hospital · 1 shared drug class
- Inova Health Care Services · 1 shared drug class
- Kyunghee University Medical Center · 1 shared drug class
- Seoul National University Hospital · 1 shared drug class
- The First Affiliated Hospital with Nanjing Medical University · 1 shared drug class
- University Hospital, Bordeaux · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Biosensors Europe SA:
- Biosensors Europe SA pipeline updates — RSS
- Biosensors Europe SA pipeline updates — Atom
- Biosensors Europe SA pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Biosensors Europe SA — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/biosensors-europe-sa. Accessed 2026-05-18.